ETFs positioned on AstraZeneca PLC

Name YTD change Weight AuM
+20.42%-.--% 334,922 M€
+18.79%-.--% 2,210 M€
+5.43%-.--% 1,193 M€
+25.10%-.--% 1,646 M€
-0.26%4.85% 5 M€
+23.75%4.05% 81 M€
+1.99%3.39% 94 M€
+14.04%1.83% 331 M€
+22.71%1.5% 210 M€
+12.17%1.29% 1,882 M€
+14.10%1.15% 19 M€
+6.33%1.12% 6,576 M€
+21.11%1.06% 122 M€
+13.99%1% 13 M€
+2.90%0.62% 8 M€
+7.27%0.54% 361 M€
+1.80%0.42% 8,285 M€
+9.67%0.31% 5,369 M€
+16.85%0.3% 630 M€
+26.19%0.3% 2,914 M€
-4.87%0.3% 15 M€
+23.93%0.3% 38 M€
+24.97%0.3% 100 M€
+18.86%0.3% 16 M€
+9.88%0.29% 40 M€
+22.38%0.29% 115 M€
+25.28%0.29% 138 M€
+3.14%0.28% 13,961 M€
+24.22%0.27% 6,226 M€
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100